Wells Fargo analyst Larry Biegelsen raised the firm’s price target on Glaukos to $103 from $83 and keeps an Overweight rating on the shares following quarterly results. The firm notes Glaukos reported Q4 sales in-line with pre-announcement but net loss was wider due to higher OpEx. Management reiterated $350M-$360M sales guidance and expects outsized seasonality in the second half of the year due to Infinite/iDose ramp.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on GKOS:
- Glaukos Quarterly Summary: Performance Insights and Disclosures
- GKOS Earnings this Week: How Will it Perform?
- Glaukos backs FY24 revenue view $350M-$360M, consensus $352.71M
- Glaukos raises FY23 revenue view to $313M from $307M-$310M, consensus $309.02M
- Glaukos reports preliminary Q4 revenue $81M, consensus $76.66M